Interprets the saline infusion test (SIT) to assess the probability of primary aldosteronism when a patient has a positive aldosterone-to-renin ratio (ARR) and requires confirmatory testing. Triggers include evaluating post‑infusion plasma aldosterone concentration (PAC) after a positive ARR, hypertension work‑up, or when deciding whether to proceed to adrenal venous sampling (AVS).
Scanned 9/9/2026
Install to Claude Code
npx -y skills add dromlakhani/MD2SKILL --skill esa-pa-interpret-sit --agent claude-codeInstalls into .claude/skills of the current project.
Are you the author of Esa Pa Interpret Sit?
Add the live security badge to your README — it updates automatically with every re-scan.
[](https://www.skillsdirectory.com/skills/dromlakhani-esa-pa-interpret-sit)More formats (shields.io, HTML) on the badges page.
---
name: esa-pa-interpret-sit
description: Interprets the saline infusion test (SIT) to assess the probability of primary aldosteronism when a patient has a positive aldosterone-to-renin ratio (ARR) and requires confirmatory testing. Triggers include evaluating post‑infusion plasma aldosterone concentration (PAC) after a positive ARR, hypertension work‑up, or when deciding whether to proceed to adrenal venous sampling (AVS).
---
# Interpret Saline Infusion Test for Primary Aldosteronism
## STEP 1 — Gather Information
- Obtain post‑infusion plasma aldosterone concentration (PAC) from the saline infusion test (2 L of 0.9% saline over 4 h, recumbent or seated).
- Confirm baseline cortisol is lower than post‑infusion cortisol (for seated SIT) to exclude an ACTH effect.
- Verify patient has a positive ARR, hypertension (sustained BP >150/100 mm Hg or resistant), and has discontinued mineralocorticoid receptor antagonists for ≥4 weeks.
- Ensure no severe uncontrolled hypertension, cardiac arrhythmia, severe hypokalemia, or renal insufficiency that would contraindicate the test.
## STEP 2 — Rule In / Rule Out
- If post‑infusion PAC ≤ 5 ng/dL (≤ 140 pmol/L) → **rule out** primary aldosteronism (PA unlikely).
- If post‑infusion PAC ≥ 10 ng/dL (≥ 280 pmol/L) → **rule in** primary aldosteronism (very probable PA).
- If post‑infusion PAC is between 5 ng/dL and 10 ng/dL (140–280 pmol/L) → proceed to Step 3 (indeterminate range).
## STEP 3 — Classify or Stratify
- For indeterminate PAC (5–10 ng/dL), apply the cutoff of 6.8 ng/dL (190 pmol/L) that offers the best sensitivity/specificity trade‑off.
- PAC < 6.8 ng/dL → lower probability of PA (consider repeat SIT or alternative confirmatory test).
- PAC ≥ 6.8 ng/dL → higher probability of PA (proceed to subtype testing).
## STEP 4 — Decide
- PAC ≤ 5 ng/dL: Exclude PA; no further confirmatory testing needed; manage hypertension conventionally.
- PAC ≥ 10 ng/dL: Diagnose PA; proceed to adrenal venous sampling (AVS) for lateralization and subtype classification.
- PAC 5–10 ng/dL:
- If PAC < 6.8 ng/dL: Repeat SIT or perform fludrocortisone suppression test (FST) to clarify.
- If PAC ≥ 6.8 ng/dL: Proceed to AVS for lateralization.
## Clinical Guardrails / Mimics / Pitfalls
- Do not perform SIT in patients with severe uncontrolled hypertension, cardiac arrhythmia, severe hypokalemia, or renal insufficiency.
- Avoid interpreting SIT without confirming adequate sodium status and withdrawal of interfering medications (MRAs, ACE‑I/ARBs, β‑blockers, NSAIDs) for at least 2–4 weeks.
- Recumbent SIT has lower sensitivity; prefer seated SIT when available for better diagnostic accuracy.
- Do not rely solely on SIT if baseline cortisol is not suppressed (risk of false‑positive due to ACTH surge).
- Indeterminate results (5–10 ng/dL) should not be used to definitively rule in or out PA without additional testing.
## Concrete Clinical Example
A 48‑year‑old patient with resistant hypertension and a positive ARR undergoes a seated saline infusion test. Post‑infusion PAC measures 7.2 ng/dL (202 pmol/L). Since the value lies between 5–10 ng/dL, the 6.8 ng/dL cutoff is applied: PAC ≥ 6.8 ng/dL indicates higher probability of PA. The clinician proceeds to adrenal venous sampling for lateralization, which later confirms unilateral aldosterone‑producing adenoma.
**Source:** The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, DOI:10.1210/jc.2015-4061
Is this your skill, or is something wrong with this listing? Request removal or report an issue. Author removals are honored within 72 hours.
No comments yet. Be the first to comment!